Clinical trials in Madrid – page 140

3 330 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Madrid at a glance

3 330

clinical trials

Research sites24

Quick filters

3 330 trials in Madrid

Open in trial search

Ovarian cancer

Not recruiting

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo

Phase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:INCB123667
Sponsor:Incyte Corp.

Contact Research Centre

Hidradenitis

Not recruiting

A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

Investigational

A study to evaluate the effectiveness and safety of BFB759 in adults with moderate to severe hidradenitis suppurativa

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:BFB759
Sponsor:Bluefin Biomedicine Inc.

Contact Research Centre

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Argipressin
Sponsor:Amgen Inc.

Contact Research Centre

Hidradenitis

Not recruiting

A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

A Study to Evaluate the Safety and Effectiveness of Ritlecitinib Tosilate in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Colitis ulcerative+1

Not recruiting

A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis

Investigational

A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study to evaluate the effect of baxdrostat and dapagliflozin in reducing protein in the urine for patients with chronic kidney disease and high blood pressure

Registered drug

A study to evaluate the effect of baxdrostat and dapagliflozin in reducing protein in the urine for patients with chronic kidney disease and high blood pressure

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Baxdrostat
Sponsor:AstraZeneca AB

Contact Research Centre

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Basal cell carcinoma

Not recruiting

A study to evaluate the safety and effectiveness of BO-112 injections in patients with resectable primary basal cell carcinoma.

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of BO-112 injections in patients with resectable primary basal cell carcinoma.

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Polyinosinic:polycytidylic Acid
Sponsor:Highlight Therapeutics S.L.

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Exelixis Inc.

Contact Research Centre

Small cell lung cancer

Not recruiting

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo

Evaluation of HLX10 Combined with Chemotherapy and Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized, Double-Blind Study

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:Shanghai Henlius Biotech Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cobolimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

Lupus skin manifestations
Platelet disorders
Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

Diabetes management
Weight control
Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

MS treatment in young patients
Stroke intervention
Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

Vaccine development
Immune response
Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

Lymphoma treatment
Bladder cancer therapy
Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Back to Spain All countries